A Single-center, Randomized, Double-blinded, Placebo-controlled, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of NCP112
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- NovaCell Technology Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05638165
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath